Literature DB >> 26568023

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.

Francesco Massari1, Chiara Ciccarese1, Matteo Santoni2, Antonio Lopez-Beltran3, Marina Scarpelli4, Rodolfo Montironi4, Liang Cheng5,6.   

Abstract

Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

Entities:  

Keywords:  fibroblast growth factor receptor; kidney; personalized medicine; precision medicine; renal cell carcinoma; targeted therapy; vascular endothelial growth factor receptor

Mesh：

Substances：

Year:  2015        PMID： 26568023     DOI： 10.1586/14737140.2015.1110488

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  9 in total

Review 1.  Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Nizar M Tannir; Sumanta K Pal; Michael B Atkins
Journal:  Oncologist       Date:  2018-02-27

2.  Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer.

Authors:  Sherry Bhalla; Kumardeep Chaudhary; Ritesh Kumar; Manika Sehgal; Harpreet Kaur; Suresh Sharma; Gajendra P S Raghava
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

3.  Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.

Authors:  Jianhui Ma; Yan Song; Jianzhong Shou; Yuxian Bai; Hanzhong Li; Xiaodong Xie; Hong Luo; Xiubao Ren; Jiyan Liu; Dingwei Ye; Xianzhong Bai; Cheng Fu; Shukui Qin; Jinwan Wang; Ai-Ping Zhou
Journal:  Front Oncol       Date:  2020-05-07       Impact factor: 6.244

Review 4.  Inhibition of FGF2-Mediated Signaling in GIST-Promising Approach for Overcoming Resistance to Imatinib.

Authors:  Sergei Boichuk; Aigul Galembikova; Ekaterina Mikheeva; Firuza Bikinieva; Aida Aukhadieva; Pavel Dunaev; Dinar Khalikov; Semen Petrov; Refat Kurtasanov; Elena Valeeva; Igor Kireev; Vera Dugina; Anna Lushnikova; Maria Novikova; Pavel Kopnin
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

Review 5.  FGF Family: From Drug Development to Clinical Application.

Authors:  Qi Hui; Zi Jin; Xiaokun Li; Changxiao Liu; Xiaojie Wang
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

6.  Peptide ligands targeting FGF receptors promote recovery from dorsal root crush injury via AKT/mTOR signaling.

Authors:  Ying Zhao; Qiang Wang; Chen Xie; Yuling Cai; Xue Chen; Yuhui Hou; Liu He; Jianping Li; Min Yao; Shuangxi Chen; Wutian Wu; Xiaojia Chen; An Hong
Journal:  Theranostics       Date:  2021-11-02       Impact factor: 11.556

7.  Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation.

Authors:  Abeda Jamadar; Nidhi Dwivedi; Sijo Mathew; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

8.  Risk stratification and pathway analysis based on graph neural network and interpretable algorithm.

Authors:  Bilin Liang; Haifan Gong; Lu Lu; Jie Xu
Journal:  BMC Bioinformatics       Date:  2022-09-27       Impact factor: 3.307

Review 9.  Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice.

Authors:  Meghan Salgia; Jacob Adashek; Paulo Bergerot; Sumanta K Pal
Journal:  Kidney Cancer       Date:  2017-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.